Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

August 11, 2023
Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-termMizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

Jared Holz, Mizuho healthcare strategist, joins ‘Squawk Box’ to discuss Novo Nordisk’s quarterly earnings results, which hiked its outlook for 2023 after reporting a 30% increase in sales for the first half of the year, powered by strong demand for its weight loss drugs, and more.

Share This

Latest Mizuho News

Payment stocks down due policy uncertainty, says Mizuho’s Dan Dolev

Payment stocks down due policy uncertainty, says Mizuho’s Dan Dolev

January 13, 2026
Why Dutch Bros is a top stock pick for 2026, while Starbucks lags

Why Dutch Bros is a top stock pick for 2026, while Starbucks lags

December 23, 2025
Keeping current furniture tariff rates benefits home furnishings sector: Mizuho’s Bellinger

Keeping current furniture tariff rates benefits home furnishings sector: Mizuho’s Bellinger

January 2, 2026

Mizuho news from around the globe

back-to-top-blue